Table 2 Variables associated with COVID-19 Severity
From: Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma
COVID-19 Severity | ||
|---|---|---|
Predictors | Odds Ratios | CI |
Recent cytotoxic therapy | 0.63 | 0.18 – 2.19 |
Recent targeted therapy | 1.89 | 0.64 – 5.55 |
Recent immunotherapy | 0.51 | 0.19 – 1.39 |
No systemic therapy, ever | 0.91 | 0.29 – 2.87 |
Melanoma as the primary cancer (Yes) | 0.83 | 0.40 – 1.71 |
Age, per decade | ||
Linear | 0.74 | 0.46 – 1.20 |
Quadratic | 1.24 | 1.12 – 1.37 |
Sex (Male vs Female) | 1.80 | 0.96 – 3.36 |
Race (Non-Hispanic White vs Other) | 1.14 | 0.50 – 2.60 |
Sunbelt region (yes vs no) | 0.35 | 0.17 – 0.75 |
Smoking status (Ever vs Never) | 1.42 | 0.78 – 2.60 |
Obesity (yes vs no) | 0.50 | 0.27 – 0.93 |
Cardiovascular comorbidities (yes vs no) | 0.96 | 0.46 – 2.00 |
Renal disease (yes vs no) | 1.81 | 0.72 – 4.56 |
Pulmonary comorbidities (yes vs no) | 2.27 | 1.12 – 4.62 |
Diabetes (yes vs no) | 2.12 | 1.01 – 4.47 |
Immunosuppressed (yes vs no) | 1.55 | 0.66 – 3.64 |
ECOG status (1 vs 0) | 0.93 | 0.42 – 2.08 |
ECOG status (2 + vs 0) | 12.53 | 4.22 – 37.19 |
ECOG status (Unknown vs 0) | 1.49 | 0.72 – 3.07 |
Cancer status (Active, stable/responding vs remission) | 1.37 | 0.56 – 3.38 |
Cancer status (Active, progressing vs remission) | 3.22 | 1.21 – 8.58 |
Cancer status (Unknown vs remission) | 1.05 | 0.38 – 2.91 |
COVID Diagnosis (May—Aug 2020 vs Jan—Apr 2020) | 0.18 | 0.08 – 0.40 |
COVID Diagnosis (Sep—Dec 2020 vs Jan—Apr 2020) | 0.17 | 0.08 – 0.38 |
COVID Diagnosis (Jan—Apr 2021 vs Jan—Apr 2020) | 0.10 | 0.03 – 0.31 |
COVID Diagnosis (May—Aug 2021 vs Jan—Apr 2020) | 0.18 | 0.05 – 0.63 |
COVID Diagnosis (Sep—Dec 2021 vs Jan—Apr 2020) | 0.14 | 0.02 – 0.83 |